Therapeutic Nuclear Medicines Market Segmentation By Product Type (Alpha Emitters, Beta Emitters and Brachytherapy products); By Application (Bone Metastasis, Thyroid, Endocrine Tumors, Lymphoma and Others); By End-User (Ambulatory Surgical Centers, Hospitals and Radiology Clinics) - Global Demand Analysis & Opportunity Outlook 2027

Product Overview

Therapeutic nuclear medicines are primarily used for irradiation of cells and organs therapeutically. Nuclear medicines has the unique characteristics of the radioactive materials. These properties are used for the treatment of the certain medical conditions. The nuclear medicines are used for the treatment of the chronic diseases such as cancer .Some of the common application of the nuclear medicines includes treatment of over-active thyroid and thyroid cancer .The nuclear medicines are consumed in the form of liquid and capsule.

Market Size and Forecast

The global therapeutic nuclear medicines market is anticipated to expand at a significant CAGR during 2018-2027. The increasing cases of the population suffering from chronic disease coupled with rising demand for the better therapies is anticipated to boost the growth of the global therapeutic nuclear medicines market. For instance, according to WHO the total cases related to cancer is around 18.1 million in 2018. Additionally, the cases related to chronic respiratory diseases are around globe which includes large cases of asthma is anticipated to boost the growth of the overall market. The total cases of asthma is 235 million in 2018.

The global therapeutic nuclear medicines market can be segmented on the basis of product type, application, end-user and region. On the basis of product type, it is sub-segmented into alpha emitters, beta emitters and brachytherapy products. On the basis of application, it is sub-segmented into bone metastasis, thyroid, endocrine tumors, lymphoma and others. Thyroid is anticipated to be the leading sub-segment for the application segment. The increasing cases of the thyroid cancer across the globe is anticipated to boost the demand for the therapeutic nuclear medicines during the forecast period. On the basis of end-user, it is sub-segmented into ambulatory surgical centers, hospitals and radiology clinics. Hospitals is anticipated to be the leading sub-segment of the end-user segment on the account of the high availability of therapeutic medicines coupled with the rising number of consultants for the diagnosis of the chronic diseases .

By region, global therapeutic nuclear medicines market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. North America is anticipated to hold the largest market share for the global therapeutic nuclear medicines market.  The development of the technology in the region such as introduction of the new radiopharmaceuticals for the therapy and imaging is expected to propel the market growth of the therapeutic nuclear medicines in the region. Asia-Pacific is anticipated to be the fastest developing region for the global therapeutic nuclear medicines market. The rising disposable income of the population, improving healthcare standards is anticipated to fuel the market growth of the therapeutic nuclear medicines in the region. Additionally increasing government expenditure in the healthcare is anticipated to expand the therapeutic nuclear medicines market.

Market Segmentation

Our in-depth analysis segmented the global therapeutic nuclear medicines market in the following segments:

By Product Type:

• Alpha Emitters

• Ra-223

• Beta Emitters

• Rh-186
• Y-90
• I-131
• Sm-153
• Lu-177
• Others

• Brachytherapy products

• Cs-131
• Ir-192
• I-125
• Pa-103
• Others

By Application:

• Bone Metastasis
• Thyroid
• Endocrine Tumors
• Lymphoma
• Others

By End-User:

• Ambulatory Surgical Centers
• Hospitals
• Radiology Clinics

By Region

Global therapeutic nuclear medicines market is further classified on the basis of region as follows:

• North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
• Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
• Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Growth Drivers and Challenges

The increasing number of the cases related to chronic diseases coupled with the rising awareness about the nuclear medicine is anticipated to be the major growth driver for the global therapeutic nuclear medicines market. The non-invasive procedure done by using therapeutic nuclear medicine is also driving the growth of the global therapeutic nuclear medicines market. The increasing research and development in the therapeutic nuclear medicine in order to cure the patient effectively is anticipated to be one of the major growth driver for the global therapeutic nuclear medicines market.

However, costly procedure involved in the treatment, low supply and side effects involved in the treatment is anticipated to restrict the global therapeutic nuclear medicines market.

Key Players

• Bayer AG
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
• GE Healthcare
• Cardinal Health Inc.
• Mallinckrodt plc.
• Bracco Imaging S.p.A
• Lantheus Medical Imaging, Inc.
• Nordion, Inc.
• Advanced Accelerator Applications S.A.
• Eczacibasi-Monrol Nuclear Products
• IBA Molecular Imaging